首页> 外文期刊>Frontiers in Pediatrics >Use of Autologous Cord Blood Mononuclear Cells Infusion for the Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: A Study Protocol for a Placebo-Controlled Randomized Multicenter Trial [NCT03053076]
【24h】

Use of Autologous Cord Blood Mononuclear Cells Infusion for the Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: A Study Protocol for a Placebo-Controlled Randomized Multicenter Trial [NCT03053076]

机译:使用自体脐带血单核细胞输注在极端早产的新生儿中预防支气管扩张性:A研究方案,用于安慰剂控制随机多中心试验[NCT03053076]

获取原文
获取外文期刊封面目录资料

摘要

Background: Despite the rapid advance of neonatal care, bronchopulmonary dysplasia (BPD) remains a significant burden for the preterm population, and there is a lack of effective intervention. Stem cell depletion because of preterm birth is regarded as one of the underlying pathological mechanisms for the arrest of alveolar and vascular development. Preclinical and small-sample clinical studies have proven the efficacy and safety of stem cells in treating and preventing lung injury. However, there are currently no randomized clinical trials (RCTs) investigating the use of autologous cord blood mononuclear cells (ACBMNC) for the prevention of BPD in premature infants. The purpose of this study is to investigate the effects of infusion of ACBMNC for the prevention of BPD in preterm neonates 28 weeks. Methods: In this prospective, randomized controlled double-blind multi-center clinical trial, 200 preterm neonates 28 weeks gestation will be randomly assigned to receive intravenous ACBMNC infusion (5 × 10 7 cells/kg) or placebo (normal saline) within 24 h after birth in a 1:1 ratio using a central randomization system. The primary outcome will be survival without BPD at 36 weeks of postmenstrual age or at discharge, whichever comes first. The secondary outcomes will include the mortality rate, other common preterm complication rates, respiratory support duration, length, and cost of hospitalization, and long-term outcomes after a 2-year follow-up. Conclusion: This will be the first randomized, controlled, blinded trial to evaluate the efficacy of ACBMNC infusion as a prevention therapy for BPD. The results of this trial will provide valuable clinical evidence for recommendations on the management of BPD in extremely preterm infants. Clinical Trial Registration: ClinicalTrials.gov, {"type":"clinical-trial","attrs":{"text":"NCT03053076","term_id":"NCT03053076"}} NCT03053076 , registered 02/14/2017, retrospectively registered, https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0006WN4&selectaction=Edit&uid=U0002PLA&ts=2&cx=9y23d4 ( Additional File 2 ).
机译:背景:尽管新生儿护理的快速进展,但支气管扩张性发育不良(BPD)仍然是早产人的重大负担,缺乏有效的干预。由于早产出生的干细胞耗尽被认为被认为是肺泡和血管发育的潜在病理机制之一。临床前和小样本临床研究已经证明干细胞治疗和预防肺损伤的疗效和安全性。然而,目前没有随机临床试验(RCTS)研究使用自体脐带血单核细胞(ACBMNC)用于预防早产儿的BPD。本研究的目的是研究输注ACBMNC在早产新生儿&lt中预防BPD的影响。方法:在该前瞻性,随机对照双盲多中心临床试验中,200日早产&LT 28周内妊娠将被随机分配接受静脉内的ACBMNC输注(5×10 7个细胞/ kg)或安慰剂(正常盐水) 24小时出生后1:1的比例使用中央随机化系统。主要结果将在未经审计年龄的36周或放电时生存,或者在排出时,以先到者为准。二次结果将包括死亡率,其他常见的早产并发症率,呼吸支撑持续时间,长度和住院费用,以及在2年后的后续行动后的长期结果。结论:这将是第一个可随机,受控,盲化的试验,以评估ACBMNC输注作为BPD预防治疗的疗效。该试验的结果将为在极端早产儿,为BPD管理的建议提供有价值的临床证据。临床试验登记:ClinicalTrials.gov,{“类型”:"临床 - 试验“,”attrs“:{”文本“:”nct03053076“,”术语“,”NCT03053076“,”NCT03053076“。nct03053076,注册02/14/2017,回顾性注册,https://register.clinicaltrials.gov/prs/app/action/selectprotocol? sid=s0006wwn4&selectaction=edit& tuid=u0002pla&ts=2&cx=9y23d4(附加文件2)。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号